Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:33:12.614Z.
Calculation as of: 2026-10-06T15:33:12.614Z.
Quote observation: 2026-10-06T15:28:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 87a3ef4e55b06d985fb23947e4d9ae6563d80488a3a61227015f8099389db825
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$668838.00
EV/EBITDA Ratio
4.13x
TTM Avg
10.27x
3Y Avg
9.51x
5Y Avg
9.51x
Market Cap
$374618.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$827564.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$856468.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$866624.00
EV/EBITDA Ratio
N/A
TTM Avg
1464.50x
3Y Avg
6462.34x
5Y Avg
6462.34x
Market Cap
$873508.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
EV/EBITDA Ratio
N/A
TTM Avg
1.21x
3Y Avg
1.21x
5Y Avg
1.21x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HCW Biologics Inc. (HCWB) | $549273.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $668838.00 | 4.13x | 10.27x | 9.51x | 9.51x |
| Niki BioSolutions, Inc. (NIKI)vs › | $374618.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $827564.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $856468.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $866624.00 | N/A | 1464.50x | 6462.34x | 6462.34x |
| Bone Biologics Corporation (BBLG)vs › | $873508.00 | N/A | N/A | N/A | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $94334.00 | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A | 1.21x | 1.21x | 1.21x |
| PRF Technologies Ltd. (PRFX)vs › | $71682.00 | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
